Q4 2025 Krystal Biotech Inc Earnings Call Transcript
Key Points
- Krystal Biotech Inc (KRYS) reported strong revenue growth with net VYJUVEK revenue of $107.1 million in Q4, contributing to total net revenues of over $730 million since launch.
- The company achieved a gross margin of 94% for both the quarter and the full year, indicating strong profitability.
- Krystal Biotech Inc (KRYS) expanded its global reach, signing distributive agreements covering more than 20 countries, with plans to expand to over 40 countries in 2026.
- The company is making significant progress in its pipeline, with two registrational trials underway and plans to initiate two additional registrational programs in cystic fibrosis and Hailey-Hailey disease.
- Krystal Biotech Inc (KRYS) received Fast Track and Rare Pediatric Disease designations from the FDA for its pipeline programs, which could accelerate development timelines.
- Pricing negotiations in key markets like Germany and France are ongoing and are expected to continue into 2026 and 2027, respectively, which could impact revenue recognition.
- The company faces compliance challenges in Japan due to regulatory requirements that mandate patients to obtain new prescriptions every two weeks during the first year of launch.
- Operating expenses increased due to higher headcount, legal and consulting services, and marketing costs to support global launches, impacting overall profitability.
- Revenue growth may not track linearly with patient counts due to accruals, timing effects, and ongoing pricing negotiations, creating potential volatility in financial results.
- The company is not currently planning to use its cash reserves for stock buybacks or acquisitions, which may limit opportunities for shareholder returns in the near term.
Thank you for holding. We look forward to talking with you soon. Please hold the line and we'll be right back with you.
Thank you for standing by and welcome to the Krystal Biotech 4Q 2025 conference call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now like to hand the conference over to your host, Stephane Paquette, Vice President of Corporate Development.
Good morning and thank you all for joining today's call. Earlier today, we released our financial results for the fourth quarter and full year of 2025. The press release is available on our website at www.crystalbio.com.
We also filed our earnings 8-K and 10-K with the SEC earlier today. Joining me today will be Kirsh Krishnan, Chairman and Chief Executive Officer; Suma Krishnan, President of Research and Development; Christine Wilson, Senior Vice President and Head of US Commercial; Laurent Goux, Senior
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
